eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

4/2016
vol. 41
 
Share:
Share:
more
 
 
abstract:
Experimental immunology

Ellagic acid alleviates adjuvant induced arthritis by modulation of pro- and anti-inflammatory cytokines

Gamal Allam, Emad A. Mahdi, Abdullah M. Alzahrani, Abdelaziz S. Abuelsaad

(Cent Eur J Immunol 2016; 41 (4): 339-349)
Online publish date: 2017/01/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown aetiology, but it is now clear that pro-inflammatory cytokines play a central role in its pathogenesis. Ellagic acid (EA) has a variety of biological activities including anti-oxidant, anti-inflammatory, and anti-cancer properties. The aim of the present study was to evaluate the potential effect of ellagic acid on the prevention and/or treatment of adjuvant induced arthritis (AIA) model in mice. Ellagic acid treatment was started one week before AIA induction and continued for three weeks after induction of AIA. Ellagic acid treatment significantly (p  0.01) inhibited foot paw oedematous swelling and attenuated AIA-associated pathology. Ellagic acid significantly (p  0.01) reduced serum levels of pro-inflammatory cytokines: interleukin 1 (IL-1), tumor necrosis factor  (TNF-), and interleukin 17 (IL-17). However, serum levels of IL-10 and interferon  (IFN-) significantly increased (p  0.01 and p  0.05, respectively), while serum level of transforming growth factor  (TGF-) did not significantly alter with EA treatment. In conclusion, these results suggest that EA attenuated AIA-associated pathology in the mouse model by downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines.
keywords:

adjuvant induced arthritis, ellagic acid, pro-inflammatory cytokine, anti-inflammatory cytokine

references:
Ibold Y, Frauenschuh S, Kaps C, et al. (2007): Development of a high-throughput screening assay based on the 3-dimensional pannus model for rheumatoid arthritis. J Biomol Screen 12: 956-965.
Epstein FH, Choy EH, Panayi GS (2001): Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916.
Majithia V, Geraci SA (2007): Rheumatoid arthritis: diagnosis and management. Am J Med 120: 936-939.
Choy E (2012): Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 51: v3-v11.
Arend WP, Dayer JM (1995): Inhibition of the production and effects of interleukins-1 and tumor necrosis factor  in rheumatoid arthritis. Arthritis Rheum 38: 151-160.
Barksby H, Lea S, Preshaw P, et al. (2007): The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149: 217-225.
Firestein GS (2003): Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
Moreland LW, Schiff MH, Baumgartner SW, et al. (1999): Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 130: 478-486.
Feldmann M, Maini RN (2001): Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163-196.
Shmerling RH (1998): Rheumatoid arthritis. Drugs Today (Barc) 34: 649-653.
Simon AK, Seipelt E, Sieper J (1994): Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci 91: 8562-8566.
van der Graaff WL, Prins AP, Dijkmans BA, et al. (1998): Prognostic value of Th1/Th2 ratio in rheumatoid arthritis. Lancet 351: 1931.
Leipe J, Grunke M, Dechant C, et al. (2010): Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62: 2876-2885.
Nakae S, Nambu A, Sudo K, et al. (2003): Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173-6177.
Bush KA, Farmer KM, Walker JS, et al. (2002): Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 46: 802-805.
Fujimoto M, Serada S, Mihara M, et al. (2008): Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 58: 3710-3719.
de Ancos B, González EM, Cano MP (2000): Ellagic acid, vitamin C, and total phenolic contents and radical scavenging capacity affected by freezing and frozen storage in raspberry fruit. J Agric Food Chem 48: 4565-4570.
Sellappan S, Akoh CC, Krewer G (2002): Phenolic compounds and antioxidant capacity of Georgia-grown blueberries and blackberries. J Agric Food Chem 50: 2432-2438.
Mertens-Talcott SU, Talcott ST, Percival SS (2003): Low Concentrations of Quercetin and Ellagic Acid Synergistically Influence Proliferation, Cytotoxicity and Apoptosis in MOLT-4 Human Leukemia Cells. J Nutr 133: 2669-2674.
Yu Y-M, Wang Z-H, Liu C-H, et al. (2007): Ellagic acid inhibits IL-1-induced cell adhesion molecule expression in human umbilical vein endothelial cells. Br J Nutr 97: 692-698.
Anderson KC, Teuber SS (2010): Ellagic acid and polyphenolics present in walnut kernels inhibit in vitro human peripheral blood mononuclear cell proliferation and alter cytokine production. Ann N Y Acad Sci 1190: 86-96.
Chao PC, Hsu CC, Yin MC (2009): Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice. Nutr Metab (Lond) 6: 33.
Chao CY, Mong MC, Chan KC, et al. (2010): Anti-glycative and anti-inflammatory effects of caffeic acid and ellagic acid in kidney of diabetic mice. Mol Nutr Food Res 54: 388-395.
Bae JY, Choi JS, Kang SW, et al. (2010): Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation. Exp Dermatol 19: e182-e190.
Chatterjee A, Chatterjee S, Das S, et al. (2012): Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation. Acta Biochim Biophys Sin (Shanghai) 44: 565-576.
Mo J, Panichayupakaranant P, Kaewnopparat N, et al. (2013): Topical anti-inflammatory and analgesic activities of standardized pomegranate rind extract in comparison with its marker compound ellagic acid in vivo. J Ethnopharmacol 148: 901-908.
Cornélio Favarin D, Martins Teixeira M, Lemos de Andrade E, et al. (2013): Anti-inflammatory effects of ellagic acid on acute lung injury induced by acid in mice. Mediators Inflamm 2013: 164202.
Ahmad SF, Khan B, Bani S, et al. (2006): Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production. Pharmacol Res 53: 233-240.
Ahmad SF, Zoheir KM, Bakheet SA, et al. (2014): Poly (ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model. Cytokine 68: 76-85.
Soh PN, Witkowski B, Olagnier D, et al. (2009): In vitro and in vivo properties of ellagic acid in malaria treatment. Antimicrob Agents Chemother 53: 1100-1106.
Shruthi S, Sujan Ganapathy P, Rakesh Kumar S, et al. (2014): In vivo, In vitro anti-arthritic studies of Ellagic acid from Kirganelia reticulata Baill and its molecular docking. J App Pharm Sci 4: 024-031.
Wu Y, Liu J, Feng X, et al. (2005): Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 52: 3257-3268.
Nasu Y, Nishida K, Miyazawa S, et al. (2008): Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16: 723-732.
González-Chávez SA, Pacheco-Tena C, Macías-Vázquez CE, et al. (2013): Assessment of different decalcifying protocols on Osteopontin and Osteocalcin immunostaining in whole bone specimens of arthritis rat model by confocal immunofluorescence. Int J Clin Exp Pathol 6: 1972.
Sancho D, Gomez M, Viedma F, et al. (2003): CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.
J Clin Invest 112: 872-882.
Ahmed S, Anuntiyo J, Malemud CJ, et al. (2005): Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med 2: 301-308.
Shen C-L, Smith BJ, Lo D-F, et al. (2012): Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem 23: 1367-1377.
Brackertz D, Mitchell GF, Mackay IR (1977): Antigen – induced arthritis in mice. Arthritis Rheum 20: 841-850.
Doyle B, Griffiths LA (1980): The metabolism of ellagic acid in the rat. Xenobiotica 10: 247-256.
Teel RW, Martin RM (1988): Disposition of the plant phenol ellagic acid in the mouse following oral administration by gavage. Xenobiotica 18: 397-405.
Landete JM (2011): Ellagitannins, ellagic acid and their derived metabolites: a review about source, metabolism, functions and health. Food Res Int 44: 1150-1160.
Larrosa M, Gonzalez-Sarrias A, Garcia-Conesa MT, et al. (2006): Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 54: 1611-1620.
Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, et al. (2006): Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem 54: 8956-8961.
Seeram NP, Henning SM, Zhang Y, et al. (2006): Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 136: 2481-2485.
Koch AE (2005): Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 52: 710-721.
Ahmed S, Wang N, Hafeez BB, et al. (2005): Punica granatum L. extract inhibits IL-1-Induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-B in human chondrocytes in vitro. J Nutr 135: 2096-2102.
Van Vollenhoven R, Soriano A, McCarthy P, et al. (1988): The role of immunity to cartilage proteoglycan in adjuvant arthritis. Intravenous injection of bovine proteoglycan enhances adjuvant arthritis. J Immunol 141: 1168-1173.
Feige U, Schulmeister A, Mollenhauer J, et al. (1994): A constitutive 65 kDa chondrocyte protein as a target antigen in adjuvant arthritis in Lewis rats. Autoimmunity 17: 233-239.
Van de Langerijt A, Lent P, Hermus A, et al. (1994): Susceptibility to adjuvant arthritis: relative importance of adrenal activity and bacterial flora. Clin Exp Immunol 97: 33-38.
Bulani V, Kothavade P, Nagmoti D, et al. (2014): 19: Ellagic acid hydroxypropyl--cyclodextrin inclusion complex alleviates adjuvant-induced arthritis: Attenuation of oxidative stress and inflammatory mediators. Cytokine 70: 32.
Figueira M, Câmara M, Direito R, et al. (2014): Chemical characterization of a red raspberry fruit extract and evaluation of its pharmacological effects in experimental models of acute inflammation and collagen-induced arthritis. Food Funct 5: 3241-3251.
Jean-Gilles D, Li L, Ma H, et al. (2012): Anti-inflammatory effects of polyphenolic-enriched red raspberry extract in an antigen-induced arthritis rat model. J Agric Food Chem 60: 5755-5762.
Gil MI, Tomás-Barberán FA, Hess-Pierce B, et al. (2000): Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 48: 4581-4589.
Shukla M, Gupta K, Rasheed Z, et al. (2008): Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition 24: 733-743.
Firestein GS, Manning AM (1999): Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 42: 609-621.
Pope RM (2002): Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2: 527-535.
Lavanya R, Maheshwari SU, Harish G, et al. (2010): Investigation of in-vitro anti-inflammatory, anti-platelet and anti-arthritic activities in the leaves of Anisomeles malabarica Linn. Res J Pharm Biol Chem Sci 1: 745-752.
Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. (2011): Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 7: 33-42.
Umesalma S, Sudhandiran G (2010): Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-kappaB, iNOS, COX-2, TNF-αlpha, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Basic Clin Pharmacol Toxicol 107: 650-655.
Jensen JD, Dunn JH, Luo Y, et al. (2011): Ellagic acid inhibits melanoma growth in vitro. Dermatol reports 3: e36.
Ahad A, Ganai AA, Mujeeb M, et al. (2014): Ellagic acid, an NF-B inhibitor, ameliorates renal function in experimental diabetic nephropathy. Chem Biol Interact 219: 64-75.
Afaq F, Saleem M, Krueger CG, et al. (2005): Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int J Cancer 113: 423-433.
Rasheed Z, Akhtar N, Anbazhagan AN, et al. (2009): Polyphenol-rich pomegranate fruit extract (POMx) suppresses PMACI-induced expression of pro-inflammatory cytokines by inhibiting the activation of MAP Kinases and NF-B in human KU812 cells. J Inflamm (Lond) 6: 1.
Bishayee A, Thoppil RJ, Darvesh AS, et al. (2013): Pomegranate phytoconstituents blunt the inflammatory cascade in a chemically induced rodent model of hepatocellular carcinogenesis. J Nutr Biochem 24: 178-187.
Lubberts E, Koenders MI, Oppers-Walgreen B, et al. (2004): Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50: 650-659.
Weaver CT, Hatton RD, Mangan PR, et al. (2007): IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852.
Lubberts E, Koenders MI, van den Berg WB (2005): The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 7: 29-37.
Lubberts E, Joosten LA, van de Loo FA, et al. (2002): Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 51: 102-104.
Genovese M, Van den Bosch F, Roberson S, et al. (2010): LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62: 929-939.
Hueber W, Patel DD, Dryja T, et al. (2010): Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2: 52ra72-52ra72.
Filannino P, Azzi L, Cavoski I, et al. (2013): Exploitation of the health-promoting and sensory properties of organic pomegranate (Punica granatum L.) juice through lactic acid fermentation. Int J Food Microbiol 163: 184-192.
Zhu M, Xu Q, Li X-L, et al. (2014): Modulating effects of leflunomide on the balance of Th17/Treg cells in collageninduced arthritis DBA/1 mice. Cent Eur J Immunol 39: 152-158.
Guedez YB, Whittington KB, Clayton JL, et al. (2001): Genetic ablation of interferon  up– regulates interleukin– 1 expression and enables the elicitation of collagen– induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 44: 2413-2424.
Chu C, Song Z, Mayton L, et al. (2003): IFN deficient C57BL/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor V6 and V8 in arthritic joints. Ann Rheum Dis 62: 983-990.
Vermeire K, Heremans H, Vandeputte M, et al. (1997): Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 158: 5507-5513.
Manoury-Schwartz B, Chiocchia G, Bessis N, et al. (1997): High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 158: 5501-5506.
Matthys P, Vermeire K, Mitera T, et al. (1999): Enhanced autoimmune arthritis in IFN- receptor-deficient mice is conditioned by mycobacteria in Freund’s adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol 163: 3503-3510.
De Klerck B, Carpentier I, Lories RJ, et al. (2004): Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. Arthritis Res Ther 6: R220-R231.
Kelchtermans H, De Klerck B, Mitera T, et al. (2005): Defective CD4+ CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther 7: R402-R415.
Kang EH, Kown TY, Oh GT, et al. (2006): The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen. Antiviral Res 72: 100-106.
Dubey A, Park DW, Kwon JE, et al. (2015): Investigation of the biological and anti-cancer properties of ellagic acid-encapsulated nano-sized metalla-cages. Int J Nanomedicine 10: 227-240.
Irmler IM, Gajda M, Bräuer R (2007): Exacerbation of antigen-induced arthritis in IFN--deficient mice as a result of unrestricted IL-17 response. J Immunol 179: 6228-6236.
Kuruvilla A, Shah R, Hochwald G, et al. (1991): Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci 88: 2918-2921.
Thorbecke G, Shah R, Leu C, et al. (1992): Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci 89: 7375-7379.
Xu X, Zheng L, Bian Q, et al. (2015): Aberrant activation of TGF-in subchondral bone at the onset of rheumatoid arthritis joint destruction. J Bone Miner Res 30: 2033-2043.
Vanella L, Di Giacomo C, Acquaviva R, et al. (2013): Apoptotic markers in a prostate cancer cell line: Effect of ellagic acid. Oncol Rep 30: 2804-2810.
Tanaka Y, Otsuka T, Hotokebuchi T, et al. (1996): Effect of IL-10 on collagen-induced arthritis in mice. Inflamm Res 45: 283-288.
Walmsley M, Katsikis PD, Abney E, et al. (1996): Interleukin-10 inhibition of the progression of established collageninduced arthritis. Arthritis Rheum 39: 495-503.
Persson S, Mikulowska A, Narula S, et al. (1996): Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 44: 607-614.
Ye L, Wen Z, Li Y, et al. (2014): Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor t production in macrophages and repression of classically activated macrophages. Arthritis Res Ther 16: R96.
El-Shitany NA, El-Bastawissy EA, El-desoky K (2014): Ellagic acid protects against carrageenan-induced acute inflammation through inhibition of nuclear factor kappa B, inducible cyclooxygenase and proinflammatory cytokines and enhancement of interleukin-10 via an antioxidant mechanism. Int Immunopharmacol 19: 290-299.
Min S-Y, Hwang S-Y, Park K-S, et al. (2004): Induction of IL-10-producing CD4+ CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther 6: R213-219.
Vermeij EA, Broeren MG, Bennink MB, et al. (2015): Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis. Ann Rheum Dis 74: 2084-2091.
Rodgers DT, Pineda MA, McGrath MA, et al. (2014): Protection against collagen-induced arthritis in mice afforded by the parasitic worm product, ES-62, is associated with restoration of the levels of interleukin– 10– producing B cells and reduced plasma cell infiltration of the joints. Immunology 141: 457-466.
Maddaloni M, Kochetkova I, Jun S, et al. (2015): Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10-and TGF--producing CD39+ Regulatory T cells. PloS One 10: e0117825.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe